Actively Recruiting
Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)
Led by Johns Hopkins Bloomberg School of Public Health · Updated on 2026-04-17
1300
Participants Needed
2
Research Sites
1291 weeks
Total Duration
On this page
Sponsors
J
Johns Hopkins Bloomberg School of Public Health
Lead Sponsor
N
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The Division of Kidney, Urologic, and Hematologic Diseases (DKUHD) of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), in collaboration with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Heart, Lung and Blood Institute (NHLBI) funded a cooperative agreement including two Clinical Coordinating Centers (at Children's Hospital of Philadelphia and at Children's Mercy Hospital in Kansas City), a central biochemistry laboratory (at the University of Minnesota) and a Data Coordinating Center (at Johns Hopkins School of Public Health) to conduct a prospective epidemiological study of children with chronic kidney disease (CKD).
CONDITIONS
Official Title
Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 1 and 16 years for Cohorts 1 and 2
- Age between 6 months and 16 years for Cohort 3
- Age between 16 and 22 years for Cohort 4
- Estimated Schwartz GFR between 30 and 90 ml/min/1.73m2 for Cohort 1
- Estimated GFR between 45 and 90 ml/min/1.73m2 based on updated Schwartz formula for Cohort 2
- Estimated GFR 40 based on CKiD Under 25 estimating equation or kidney replacement therapy experience for Cohort 4
- Willingness and ability to provide informed consent and assent
- For Cohort 3, children with non-glomerular diagnosis and kidney disease duration less than 5 years
You will not qualify if you...
- Solid organ (other than kidney), bone marrow, or stem cell transplantation
- Cancer diagnosis with ongoing treatment or within 12 months after treatment completion
- Ongoing monitoring for cardiotoxic effects of prior chemotherapy or targeted cancer therapies
- HIV infection with detectable viral load despite antiretroviral therapy
- Current pregnancy or pregnancy within past 12 months
- Inability to complete major data collection procedures
- Not fluent in English or Spanish
- Plans to move out of participating CKiD site area (transfer possible)
- Moderate to severe congenital structural heart disease
- Genetic syndromes involving central nervous system (e.g., Down syndrome)
- History of severe to profound intellectual disability (IQ <40 or significant adaptive impairment)
- For Cohort 3, expected to receive renal replacement therapy within 6 months of enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Children's Mercy Kansas City
Kansas City, Missouri, United States, 64108
Actively Recruiting
2
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19146
Actively Recruiting
Research Team
S
Susan Furth, MD, PhD
CONTACT
B
Bradley Warady, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here